Skip to main content

Table 3 Serum PSA on each days after switching to lueprolide

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

 

Day 0

Day 1

Day 2

Day 5

Day 7

total (n = 39)

2.61 ± 3.86

2.47 ± 3.66

2.43 ± 3.75

1.95 ± 2.43

1.92 ± 2.63

3 m group (n = 10)

0.628 ± 0.611

0.614 ± 0.592

0.631 ± 0.625

0.665 ± 0.621

0.655 ± 0.614

2 m group (n = 10)

2.05 ± 4.30

1.94 ± 4.04

2.05 ± 4.31

2.01 ± 3.99

2.13 ± 4.44

1 m group (n = 19)

3.88 ± 4.21

3.66 ± 4.02

3.52 ± 4.10

2.58 ± 1.71

2.53 ± 1.68

  1. Data are presented as means ± SD (ng/ml) unless indicated otherwise
  2. PSA Prostate Specific Antigen